Cantor Fitzgerald Investment Advisors L.P. recently boosted its stake in Vanguard Short-Term Corporate Bond ETF (VCSH) by 3.5%. According to its latest SEC filing, the firm added nearly 200 shares during the second quarter, bringing its total to over 5,700 shares.
Cantor Fitzgerald Investment Advisors L.P. recently boosted its stake in Vanguard Total Bond Market ETF, increasing its holdings by 1.2% in the second quarter. According to an SEC filing, the fund now owns 55,677 shares of the ETF, amounting to $4.10 million in total value.
Cantor Fitzgerald has revised its earnings projection for United Therapeutics, raising the biotechnology firm’s estimated 2025 earnings to $28.70 per share. The announcement points to growing confidence in the company’s potential for continued expansion.
Morgan Stanley and Cantor Fitzgerald have recently revised their views on Ryan Specialty. Within a few weeks, one firm lowered its price target while the other delivered an upgrade, indicating a changing landscape for the company’s stock.
Merck & Co., Inc. is projected to achieve an earnings per share of $9.62 in fiscal year 2026, according to new estimates released by Cantor Fitzgerald analyst C. Gould. The research note was issued to investors on June 9th.
Cantor Fitzgerald has reaffirmed its ‘overweight’ rating on Capricor Therapeutics (NASDAQ: CAPR). The brokerage set a $30 price target and estimated FY2025 earnings at $1.71 per share.
Cantor Fitzgerald has reduced its FY2025 earnings per share estimate for MiMedx Group to $0.30. Analyst R. Osborn issued the revised forecast on April 16th, signaling a shift in financial expectations for the NASDAQ-listed company.
